Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Pain Induced by m-Cresol as Preservative

15 de mayo de 2026 actualizado por: Stefan Heber, Medical University of Vienna

Pain Induced by m-Cresol as Preservative - A Randomised Controlled Crossover-Trial in Healthy Volunteers

Preservatives such as m-Cresol are essential components in many subcutaneously injected medications, including insulin or human growth hormone, to prevent bacterial growth. However, clinical reports have suggested that these preservatives may cause local discomfort or pain at the injection site, which can negatively impact treatment adherence. While m-Cresol is widely used, its direct contribution to injection-site pain has not yet been investigated in a prospective clinical trial.

This study aims to investigate whether subcutaneous injection of m-Cresol at concentrations commonly used in clinical practice (0.1% and 0.25%) cause significantly more pain than a preservative-free control solution. In a randomized, double-blind crossover design, healthy volunteers will receive three separate injections in a belly fold. Participants will rate their pain every 5 seconds until it subsides. The findings will help determine if m-Cresol is a primary source of injection-site pain and could lead to the development of more comfortable drug formulations.

Descripción general del estudio

Descripción detallada

Background and Objective:

m-Cresol has been used since 1980 to limit bacterial growth in parenteral medications. Although it is generally considered safe, evidence for local side effects has appeared in case reports and a clinical trial where changing the preservative led to a disappearance of local discomfort. This suggests that the preservative itself, rather than the active drug or the pH of the solution, may be responsible for a pain sensation. The objective of this study is to systematically evaluate if subcutaneous injection of m-Cresol at clinically relevant concentrations causes pain in humans.

Study Design:

This is a randomized, double-blind, placebo-controlled, 3-period crossover trial in healthy volunteers (n=18). To ensure an unbiased assessment and control for potential order effects, a Williams balanced design is utilized for the randomization of treatment sequences.

Methodology:

Familiarization: Participants first receive an unblinded injection of control solution to become accustomed to the experimental procedure and the numerical pain rating scale.

Interventions: Subjects receive three randomized, double-blind 300 µl subcutaneous injections at different spots on a belly fold, separated by at least 3 cm. The treatments include:

  1. m-Cresol at 0.1%
  2. m-Cresol at 0.25%
  3. Control solution. Pain Assessment: For each injection, pain intensity is recorded every 5 seconds using a numerical pain rating scale (0-100) until no pain is reported for 30 consecutive seconds. The pain caused by the needle insertion itself is rated separately before the injection begins to serve as a covariate for the statistical analysis.

Statistical Analysis:

The primary endpoint is the Area Under the Curve (AUC) of the subjective pain ratings over time. Comparisons will be made between the different m-Cresol concentrations and the vehicle control using a linear mixed model to test the primary hypotheses.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

18

Fase

  • Fase temprana 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Descripción

Inclusion criteria

  • Age between 18 and 70 years
  • Full legal capacity Exclusion criteria
  • Participant of another study, ongoing or within the last four weeks
  • Current medication intake (except hormonal contraception) or drug abuse
  • Female subjects: Positive pregnancy test or breastfeeding
  • Body temperature above 38°C, verified by infrared thermometer
  • Known allergic diseases, in particular asthmatic disorders and skin diseases
  • Sensory deficit, skin disease or hematoma of unknown origin in the examination of the test site

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: m-Cresol 0.1%
Participants receive a 300 µl subcutaneous injection of m-Cresol at a concentration of 0.1%.
A preservative administered subcutaneously at 0.1%, a common concentration used in medicines.
Experimental: m-Cresol 0.25%
Participants receive a 300 µl subcutaneous injection of m-Cresol at a concentration of 0.25%.
A preservative administered subcutaneously at 0.25%, a common concentration used in medicines.
Comparador de placebos: Control solution
Participants receive a 300 µl subcutaneous injection of control solution.
A control solution administered subcutaneously.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Area Under the Curve (AUC) of Pain Intensity
Periodo de tiempo: From injection start until pain subsides (approximately 15-60 seconds per injection).
Total pain burden calculated as the Area Under the Curve of serial pain ratings (0-100 numerical pain rating scale) recorded every 5 seconds from the start of injection until no pain is reported for 30 seconds.
From injection start until pain subsides (approximately 15-60 seconds per injection).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Michael J.M. Fischer, Medical University of Vienna

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

25 de mayo de 2026

Finalización primaria (Estimado)

8 de junio de 2026

Finalización del estudio (Estimado)

8 de junio de 2026

Fechas de registro del estudio

Enviado por primera vez

15 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

15 de mayo de 2026

Publicado por primera vez (Actual)

22 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

Descripción del plan IPD

De-identified individual participant data (IPD), including pain ratings, time-stamped injection responses, and basic demographics (age, sex), will be shared alongside the publication of the primary results. Only data used in the main publication and relevant supplementary analyses will be included.

Marco de tiempo para compartir IPD

IPD will be made available at the time of publication of the primary resultsarticle, as a supplementary file.

Criterios de acceso compartido de IPD

All individuals who have access to the published article will be able to access the individual participant data (IPD) and supporting information as supplementary material. No special request or data use agreement is required.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir